Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study-Reference-Cited by-同舟云学术

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Published:2021-01 Issue: Volume:151 Page:20-24
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yamamoto N.,Seto T.,Nishio M.,Goto K.,Yamamoto N.,Okamoto I.,Yamanaka T.,Tanaka M.,Takahashi K.,Fukuoka M.

Funder

Chugai Pharmaceutical

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

3. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma;Turley;Clin. Cancer Res.,2012

4. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study;Seto;Lancet Oncol.,2014

5. Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results;Seto;Drug Saf.,2018

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

3. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

4. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Cancers;2024-03-18

5. Advancements in NSCLC;American Journal of Clinical Oncology;2024-02-20